We compared the changes in pathway phenotypes of mTOR inhibitor sensitive and resistant tumors using gene expression data from a neoadjuvant clinical trial of ER+ BC patients receiving everolimus (Sabine et al., 2010). This evidence concerns the gene ESR1 and breast cancer.